Education
About Us
Working with TipRanks
Follow Us
Omeros Corp (OMER)
NASDAQ:OMER
OMER Stock Chart & Stats
$7.52
-$0.23(-2.31%)
At close: 4:00 PM EST
$7.52
-$0.23(-2.31%)
Day’s Range― - ―
52-Week Range$2.95 - $13.60
Previous CloseN/A
Volume193.12K
Average Volume (3M)6.30M
Market Cap
$626.05M
Enterprise Value$599.04M
Total Cash (Recent Filing)$36.09M
Total Debt (Recent Filing)$191.61M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Mar 03, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding70,900,460
10 Day Avg. Volume2,077,952
30 Day Avg. Volume6,302,146
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)-3.15
Price to Sales (P/S)0.00
P/FCF Ratio-3.86
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-56.54
Enterprise Value/Ebitda-5.24
Forecast
1Y Price Target
$13.11Price Target Upside74.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StabilityNovo Nordisk is in-licensing the global rights to OMS-906 as part of a potential total $2.1B agreement, which includes a $240MM upfront payment that allows OMER to address near-term debt obligations and provides operational runway for over 12 months.
Market RecognitionPre-approval information exchanges with transplant centers, hospitals, and payers have been favorable, reflecting broad recognition of narsoplimab’s benefit-risk profile and dosing regimen.
Regulatory Approval ProcessOMER submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in June 2025, which has been validated and is now under review by the Committee for Medicinal Products for Human Use.
Bears Say
Dataset LimitationsThere is skepticism of FDA approval of narsoplimab given the limited clinical dataset from open-label trials and the lack of new clinical data to support a positive regulatory decision.
Development RestrictionsOMER is restricted from developing or commercializing products targeting MASP-3 and certain other alternative pathway targets, with limited exceptions for retained preclinical program rights.
FDA Approval ConcernsSkepticism for narsoplimab approval has increased recently with the unveiling of details on the historical external controls and recent FDA CRLs on programs using historical controls for data comparisons.
Omeros News
OMER FAQ
What was Omeros Corp’s price range in the past 12 months?
Omeros Corp lowest stock price was $2.95 and its highest was $13.60 in the past 12 months.
What is Omeros Corp’s market cap?
Omeros Corp’s market cap is $626.05M.
When is Omeros Corp’s upcoming earnings report date?
Omeros Corp’s upcoming earnings report date is Mar 03, 2026 which is in 73 days.
How were Omeros Corp’s earnings last quarter?
Omeros Corp released its earnings results on Nov 13, 2025. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.447 by -$0.023.
Is Omeros Corp overvalued?
According to Wall Street analysts Omeros Corp’s price is currently Undervalued.
Does Omeros Corp pay dividends?
Omeros Corp does not currently pay dividends.
What is Omeros Corp’s EPS estimate?
Omeros Corp’s EPS estimate is -0.52.
How many shares outstanding does Omeros Corp have?
Omeros Corp has 70,900,460 shares outstanding.
What happened to Omeros Corp’s price movement after its last earnings report?
Omeros Corp reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.447. Following the earnings report the stock price went up 25.318%.
Which hedge fund is a major shareholder of Omeros Corp?
Currently, no hedge funds are holding shares in OMER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omeros Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.11 (74.34% Upside)
$13.11 (74.34% Upside)
Blogger Sentiment
Neutral
OMER Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 61.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.1%
Last 30 Days ▲ 10.6%
Last 30 Days ▲ 10.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-40.73%
Trailing 12-Months
Company Description
Omeros Corp
Omeros Corporation (OMER) is a biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics for various medical conditions. The company operates primarily in the field of inflammation, coagulopathies, and central nervous system disorders. Omeros' lead product, Omidria, is used in cataract and lens replacement surgery to prevent intraoperative miosis and reduce postoperative ocular pain. Additionally, the company is engaged in multiple clinical-stage development programs targeting conditions such as complement-mediated diseases and addiction.
OMER Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Omeros Corporation's earnings call highlighted a strategic partnership with Novo Nordisk, significant progress in regulatory approvals for Yartemlia, and improved financial positioning through debt repayment. Despite reporting a higher net loss and cash burn, the company's robust pipeline and upcoming milestones position it for potential future success.View all OMER earnings summariesOMER Stock 12 Month Forecast
Average Price Target
$13.11
▲(74.34% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Abeona Therapeutics
―
I-MAB
―
Foghorn Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
3.32% Insiders
6.62% Mutual Funds
13.73% Other Institutional Investors
67.28% Public Companies and Individual Investors